CytomX Therapeutics has been granted a patent for polypeptides with a cleavable moiety that is a substrate for proteases matriptase and u-plasminogen activator. The patent covers activatable antibodies and methods for therapeutic, diagnostic, and prophylactic applications. GlobalData’s report on CytomX Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights CytomX Therapeutics Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on CytomX Therapeutics, Personalized cancer vaccines was a key innovation area identified from patents. CytomX Therapeutics's grant share as of January 2024 was 29%. Grant share is based on the ratio of number of grants to total number of patents.

Activatable molecule with cleavable moiety substrate for matriptase

Source: United States Patent and Trademark Office (USPTO). Credit: CytomX Therapeutics Inc

The granted patent (Publication Number: US11884746B2) discloses a method for manufacturing an activatable molecule containing a cleavable moiety (CM) that serves as a substrate for matriptase. The method involves expressing and recovering an isolated polypeptide that includes a specific CM amino acid sequence (LSGRSANH - SEQ ID NO: 307) recognized by matriptase. Additionally, the isolated polypeptide may include other moieties (M) positioned either amino (N) terminally to the CM (MN), carboxyl (C) terminally to the CM (MC), or a combination of both.

Furthermore, the patent claims specify that the isolated polypeptide can contain masking moieties, antibodies, proteins, therapeutic agents, antineoplastic agents, toxic agents, drugs, detectable moieties, diagnostic agents, or affinity tags as part of the MN and MC moieties. In a specific embodiment, the isolated polypeptide may comprise a CM amino acid sequence of DRLSGRSANHKK (SEQ ID NO: 309). This method allows for the controlled activation of the molecule by matriptase, offering potential applications in various fields such as drug delivery, diagnostics, and targeted therapies.

To know more about GlobalData’s detailed insights on CytomX Therapeutics, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies